M&A and equity raisings

6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

US deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

124 deals · US$156bndisclosed · Biotech · Clear

Columns
M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Jun 2026 Vega Therapeutics Star TherapeuticsIncyteAcquisitionCompleted1,250.0Biotech+2 Lazard (buy-side)Evercore (sell-side)Morgan Stanley (sell-side)Fenwick & West (sell-side)Goodwin (buy-side)
Jun 2026 Standard BioTools ––MergerPending460.0Biotech+2 Wedbush Securities (sell-side)Fenwick & West (sell-side)Centerview Partners (buy-side)Freshfields (buy-side)Richards, Layton & Finger (buy-side)UBS (buy-side)
Jun 2026 Genesis Molecular AI –IncyteStakeAnnounced40.0AI+1 Goodwin (buy-side)
Jun 2026 Avenzo Therapeutics –RallybioAcquisitionPending–Biotech+2 Leerink Partners (sell-side)Cooley (sell-side)Evercore (buy-side)Citizens JMP (buy-side)Ropes & Gray (buy-side)
Jun 2026 Sevasemten and Edgewise muscular dystrophy business Edgewise TherapeuticsServierAsset saleCompleted1,550.0Biotech+2 LazardCenterview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)
May 2026 Curevo Vaccine –Eli LillyAcquisitionPending1,500.0Biotech+1 Cooley (sell-side)Centerview Partners (sell-side)
May 2026 Vaccine Company –LillyAcquisitionAnnounced1,550.0Biotech+1 Lazard (sell-side)Cooley (sell-side)
May 2026 Engage Bio –Eli LillyAcquisitionAnnounced202.0Biotech+1 Cooley (sell-side)
May 2026 Mentari Therapeutics –InMed PharmaceuticalsAcquisitionAnnounced–Biotech+1 Wedbush Securities (sell-side)Gibson Dunn (sell-side)Lucid Capital Markets (buy-side)Norton Rose Fulbright (buy-side)
May 2026 Orphai Therapeutics –Quince TherapeuticsAcquisitionCompleted–Biotech+2 Cooley (sell-side)LifeSci Capital (buy-side)Dorsey & Whitney (buy-side)Oppenheimer & Co. (buy-side)Gibson Dunn (buy-side)
May 2026 Anagram Therapeutics ––StakeAnnounced–Biotech+2 Goodwin (sell-side)
May 2026 CDMO and Cell Solutions businesses of Charles River Laboratories Charles River Laboratories InternationalGI PartnersAsset saleCompleted–Pharma Services+2 Moelis & Company (buy-side)Ropes & Gray (buy-side)
May 2026 Perfuse Therapeutics –BayerAcquisitionAnnounced300.0Biotech+2 Goodwin (sell-side)
May 2026 Candid Therapeutics –UCBAcquisitionAnnounced2,200.0Biotech+1 LazardCooley (sell-side)
May 2026 LimmaTech Biologics AG –Eli Lilly and CompanyAcquisitionPending780.0Biotech Goodwin (sell-side)Kirkland & Ellis (buy-side)
May 2026 Replay –LEO PharmaAcquisitionAnnounced50.0Biotech+2 Latham & Watkins (buy-side)
Apr 2026 KalVista Pharmaceuticals –Chiesi GroupAcquisitionCompleted1,900.0Pharma+2 Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Fenwick & West (sell-side)Jefferies (sell-side)Lazard (buy-side)Ropes & Gray (buy-side)
Apr 2026 Shionogi-Apnimed Sleep Science ApnimedShionogi & Co.AcquisitionAnnounced100.0Pharma+1 Goodwin (sell-side)
Apr 2026 Emalex Biosciences –Teva PharmaceuticalsAcquisitionAnnounced700.0Pharma+1 Centerview Partners (sell-side)Bradley Arant Boult Cummings (sell-side)Evercore (buy-side)Faegre Drinker Biddle & Reath (buy-side)
Apr 2026 Ajax Therapeutics –Eli Lilly and CompanyAcquisitionAnnounced2,300.0Biotech+2 Cooley (sell-side)Kirkland & Ellis (sell-side)Ropes & Gray (buy-side)
Apr 2026 XOMA Royalty –Ligand PharmaceuticalsAcquisitionCompleted739.0Specialty finance and leasing+2 Leerink Partners (sell-side)H.C. Wainwright & Co. (sell-side)Gibson Dunn (sell-side)Stifel (buy-side)Citi (buy-side)Paul Hastings (buy-side)Collected Strategies (buy-side)
Apr 2026 Kashiv BioSciences –Amneal PharmaceuticalsAcquisitionCompleted375.0Biotech+2 J.P. Morgan (sell-side)Holland & Knight (sell-side)Goldman Sachs (buy-side)Richards, Layton & Finger (buy-side)Simpson Thacher & Bartlett (buy-side)Boston Consulting Group (buy-side)
Apr 2026 Kelonia Therapeutics –Eli Lilly and CompanyAcquisitionAnnounced7,000.0Biotech+2 Goodwin (sell-side)Jefferies (sell-side)Kirkland & Ellis (buy-side)
Apr 2026 Neurona Therapeutics –UCBAcquisitionAnnounced650.0Biotech+2 Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side)
Apr 2026 CrossBridge Bio –Eli Lilly and CompanyAcquisitionAnnounced300.0Biotech+2 Cooley (sell-side)
Apr 2026 Obsidian Therapeutics –Galera TherapeuticsMergerCompleted413.5Biotech+2 Goodwin (sell-side)Sidley Austin (buy-side)Leerink Partners (sell-side)Lucid Capital Markets (buy-side)
Apr 2026 Tubulis EQT Life Sciences (LSP 7 fund)Gilead SciencesAcquisitionAnnounced3,150.0Biotech+2 Goodwin (sell-side)J.P. Morgan (sell-side)CMS (sell-side)Centerview Partners (buy-side)Allen & Company (buy-side)Covington & Burling (buy-side)Arnold & Porter (buy-side)Venable (buy-side)
Apr 2026 Soleno Therapeutics –Neurocrine BiosciencesAcquisitionCompleted2,900.0Biotech+2 Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side)
Apr 2026 Exclusive global rights to TAK-063 (balipodect) Takeda Pharmaceutical Co.Axsome TherapeuticsAsset saleCompleted–Pharma+1 Sidley Austin (buy-side)
Apr 2026 Modeyso commercial sales royalties Former Oncoceutics Inc. securityholdersHealthCare RoyaltyAsset saleAnnounced–Specialty finance and leasing+3 Latham & Watkins (sell-side)
Mar 2026 Apellis Pharmaceuticals –BiogenAcquisitionAnnounced5,600.0Biotech+2 Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side)
Mar 2026 Centessa Pharmaceuticals –Eli Lilly and CompanySchemePending6,300.0Biotech+1 Centerview Partners (sell-side)Jefferies (sell-side)Goodwin (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Mar 2026 Kezar Life Sciences –Aurinia PharmaceuticalsAcquisitionAnnounced51.5Biotech+1 TD Securities (sell-side)Cooley (sell-side)
Mar 2026 AnaptysBio outstanding common stock –AnaptysBioBuy-backAnnounced100.0Biotech+1 Piper Sandler (buy-side)
Mar 2026 Eos SENOLYTIX –PulmatrixMergerAnnounced–Biotech+1 Palladium Capital Group (buy-side)Evolution Venture Partners (sell-side)Wilk Auslander (sell-side)Gemini Valuation Services (buy-side)Haynes Boone (buy-side)
Mar 2026 Ouro Medicines –GileadAcquisitionAnnounced1,675.0Biotech+1 Paul, WeissGoodwin (sell-side)Centerview Partners (buy-side)
Mar 2026 Terns Pharmaceuticals –Merck & Co.AcquisitionAnnounced6,700.0Biotech+2 Centerview Partners (sell-side)Freshfields (sell-side)Jefferies (sell-side)Covington & Burling (buy-side)Gibson Dunn (buy-side)
Mar 2026 Pikavation SynnovationNovartisAcquisitionAnnounced2,000.0Biotech+2 Goodwin (sell-side)Centerview Partners (sell-side)
Mar 2026 Lisata Therapeutics –Kuva LabsAcquisitionPending–Biotech+2 Mintz (sell-side)H.C. Wainwright & Co. (sell-side)Goodwin (buy-side)Campaign Management (buy-side)
Mar 2026 Day One Biopharmaceuticals –ServierAcquisitionPending2,500.0Biotech+2 Centerview Partners (sell-side)Fenwick & West (sell-side)Goldman Sachs (buy-side)Baker McKenzie (buy-side)Innisfree M&A (buy-side)
Mar 2026 Unleash-owned rights to UIO-524, UIO-525 and UIO-526 Unleash Immuno OncolyticsTransCode TherapeuticsAsset salePending–Biotech+2 Tungsten Advisors
Mar 2026 Cullgen –Gyre TherapeuticsAcquisitionPending300.0Biotech+1 Mintz (sell-side)Moelis & Company (buy-side)Gibson Dunn (buy-side)
Mar 2026 Candid Therapeutics –RallybioAcquisitionPending–Biotech+1 Wedbush Securities (sell-side)Cooley (sell-side)Evercore (buy-side)Citizens JMP (buy-side)Ropes & Gray (buy-side)
Mar 2026 Transcend Therapeutics –OtsukaAcquisitionAnnounced700.0Biotech+2 Kirkland & Ellis (sell-side)Goodwin (sell-side)Centerview Partners (sell-side)Skadden, Arps, Slate, Meagher & Flom (buy-side)
Feb 2026 Precision NeuroMed –Brainlab SEStakeCompleted–Biotech+2 Sidley Austin (sell-side)
Feb 2026 AiCuris Anti-infective Cures AG –Veloxis PharmaceuticalsAcquisitionAnnounced913.0Pharma+1 Gibson Dunn (sell-side)Freshfields (buy-side)
Feb 2026 35Pharma –GSKAcquisitionAnnounced950.0Biotech+1 Cooley (sell-side)Centerview Partners (sell-side)Paul, Weiss (buy-side)
Feb 2026 Arcellx –Gilead SciencesAcquisitionAnnounced7,800.0Biotech+2 Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Morgan Stanley (buy-side)Ropes & Gray (buy-side)Innisfree M&A (buy-side)
Feb 2026 Faeth Therapeutics –Sensei BiotherapeuticsAcquisitionCompleted–Biotech+2 Cooley (sell-side)Lucid Capital Markets (buy-side)Sidley Austin (buy-side)
Feb 2026 Avadel Pharmaceuticals –AlkermesSchemeCompleted–Pharma+1 Goldman Sachs (sell-side)Morgan Stanley (sell-side)J.P. Morgan (buy-side)

Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.